User assessment of Norditropin NordiFlex®,a new prefilled growth hormone pen:a Phase IV multicenter prospective study
Maithé Tauber,1 Delphine Jaquet,2 Monique Jesuran-Perelroizen,3 Marc Petrus,4 Anne Marie Bertrand,5 Regis Coutant6NordiFlex® French Study Group1Hôpital des Enfants, Toulouse, 2Novo Nordisk, La Défense Cédex, 3Cabinet d’Endocrinologie P&...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-05-01
|
| Series: | Patient Preference and Adherence |
| Online Access: | http://www.dovepress.com/nbspuser-assessment-of-norditropin-nordiflexrega-new-prefilled-growth--a13146 |
| _version_ | 1818991732675575808 |
|---|---|
| author | Tauber M Jaquet D Jesuran-Perelroizen M Petrus M Bertr AM Coutant R |
| author_facet | Tauber M Jaquet D Jesuran-Perelroizen M Petrus M Bertr AM Coutant R |
| author_sort | Tauber M |
| collection | DOAJ |
| description | Maithé Tauber,1 Delphine Jaquet,2 Monique Jesuran-Perelroizen,3 Marc Petrus,4 Anne Marie Bertrand,5 Regis Coutant6NordiFlex® French Study Group1Hôpital des Enfants, Toulouse, 2Novo Nordisk, La Défense Cédex, 3Cabinet d’Endocrinologie Pédiatrique, Toulouse, 4Centre Hospitalier de Bigorre, Tarbes, 5Centre Hospitalier Universitaire de Besançon, Besançon, 6Centre Hospitalier Universitaire Angers, Angers, FranceBackground/aim: In growth disorders, ensuring long-term growth hormone therapy (GHT) remains a challenge that might compromise the clinical outcome. Consequently, strategies aiming at alleviating the burden of daily injection might improve the treatment benefit. The study reported here was performed to assess the ease of use of Norditropin NordiFlex® (Novo Nordisk, Princeton, NJ, USA) compared with that of the devices previously used in children treated with GHT with recombinant somatropin.Methods: This Phase IV prospective, multicenter, open-label study was conducted in France. All patients received Norditropin NordiFlex for 6 weeks. Oral questionnaires were administered by the physician to the patients and/or the parents at inclusion and at the final visit.Results: This study included 103 patients aged between 6 and 17 years. The patients assessed Norditropin NordiFlex as significantly easier to use than their previous device (median value = 7.5, P < 0.001). Almost three-quarters of patients (64.4%) preferred Norditropin NordiFlex to their previous device. Among physicians and nurses, 73% assessed Norditropin NordiFlex training as "very easy" and 26% as "easy." Norditropin NordiFlex improved patient autonomy, with 41% of patients able to self-inject the treatment.Conclusion: This study has shown that Norditropin NordiFlex is reliable, safe, and easy to use and most study patients preferred it to their previous device. These characteristics may improve the adherence to GHT.Keywords: growth hormone therapy, adherence, injection devices, preference, ease of use |
| first_indexed | 2024-12-20T20:14:57Z |
| format | Article |
| id | doaj.art-3b84d9bbb1fd4898b217fe04e013cebf |
| institution | Directory Open Access Journal |
| issn | 1177-889X |
| language | English |
| last_indexed | 2024-12-20T20:14:57Z |
| publishDate | 2013-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj.art-3b84d9bbb1fd4898b217fe04e013cebf2022-12-21T19:27:44ZengDove Medical PressPatient Preference and Adherence1177-889X2013-05-012013default455462User assessment of Norditropin NordiFlex®,a new prefilled growth hormone pen:a Phase IV multicenter prospective studyTauber MJaquet DJesuran-Perelroizen MPetrus MBertrAMCoutant RMaithé Tauber,1 Delphine Jaquet,2 Monique Jesuran-Perelroizen,3 Marc Petrus,4 Anne Marie Bertrand,5 Regis Coutant6NordiFlex® French Study Group1Hôpital des Enfants, Toulouse, 2Novo Nordisk, La Défense Cédex, 3Cabinet d’Endocrinologie Pédiatrique, Toulouse, 4Centre Hospitalier de Bigorre, Tarbes, 5Centre Hospitalier Universitaire de Besançon, Besançon, 6Centre Hospitalier Universitaire Angers, Angers, FranceBackground/aim: In growth disorders, ensuring long-term growth hormone therapy (GHT) remains a challenge that might compromise the clinical outcome. Consequently, strategies aiming at alleviating the burden of daily injection might improve the treatment benefit. The study reported here was performed to assess the ease of use of Norditropin NordiFlex® (Novo Nordisk, Princeton, NJ, USA) compared with that of the devices previously used in children treated with GHT with recombinant somatropin.Methods: This Phase IV prospective, multicenter, open-label study was conducted in France. All patients received Norditropin NordiFlex for 6 weeks. Oral questionnaires were administered by the physician to the patients and/or the parents at inclusion and at the final visit.Results: This study included 103 patients aged between 6 and 17 years. The patients assessed Norditropin NordiFlex as significantly easier to use than their previous device (median value = 7.5, P < 0.001). Almost three-quarters of patients (64.4%) preferred Norditropin NordiFlex to their previous device. Among physicians and nurses, 73% assessed Norditropin NordiFlex training as "very easy" and 26% as "easy." Norditropin NordiFlex improved patient autonomy, with 41% of patients able to self-inject the treatment.Conclusion: This study has shown that Norditropin NordiFlex is reliable, safe, and easy to use and most study patients preferred it to their previous device. These characteristics may improve the adherence to GHT.Keywords: growth hormone therapy, adherence, injection devices, preference, ease of usehttp://www.dovepress.com/nbspuser-assessment-of-norditropin-nordiflexrega-new-prefilled-growth--a13146 |
| spellingShingle | Tauber M Jaquet D Jesuran-Perelroizen M Petrus M Bertr AM Coutant R User assessment of Norditropin NordiFlex®,a new prefilled growth hormone pen:a Phase IV multicenter prospective study Patient Preference and Adherence |
| title | User assessment of Norditropin NordiFlex®,a new prefilled growth hormone pen:a Phase IV multicenter prospective study |
| title_full | User assessment of Norditropin NordiFlex®,a new prefilled growth hormone pen:a Phase IV multicenter prospective study |
| title_fullStr | User assessment of Norditropin NordiFlex®,a new prefilled growth hormone pen:a Phase IV multicenter prospective study |
| title_full_unstemmed | User assessment of Norditropin NordiFlex®,a new prefilled growth hormone pen:a Phase IV multicenter prospective study |
| title_short | User assessment of Norditropin NordiFlex®,a new prefilled growth hormone pen:a Phase IV multicenter prospective study |
| title_sort | user assessment of norditropin nordiflex reg a new prefilled growth hormone pen a phase iv multicenter prospective study |
| url | http://www.dovepress.com/nbspuser-assessment-of-norditropin-nordiflexrega-new-prefilled-growth--a13146 |
| work_keys_str_mv | AT tauberm userassessmentofnorditropinnordiflexreganewprefilledgrowthhormonepenaphaseivmulticenterprospectivestudy AT jaquetd userassessmentofnorditropinnordiflexreganewprefilledgrowthhormonepenaphaseivmulticenterprospectivestudy AT jesuranperelroizenm userassessmentofnorditropinnordiflexreganewprefilledgrowthhormonepenaphaseivmulticenterprospectivestudy AT petrusm userassessmentofnorditropinnordiflexreganewprefilledgrowthhormonepenaphaseivmulticenterprospectivestudy AT bertr userassessmentofnorditropinnordiflexreganewprefilledgrowthhormonepenaphaseivmulticenterprospectivestudy AT am userassessmentofnorditropinnordiflexreganewprefilledgrowthhormonepenaphaseivmulticenterprospectivestudy AT coutantr userassessmentofnorditropinnordiflexreganewprefilledgrowthhormonepenaphaseivmulticenterprospectivestudy |